Lymphoma (includes NHL, HL, CNS Lymphoma)
(Merck) July 9, 2019 - Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review six supplemental Biologics License Applications (sBLAs) to update the dosing frequency for KEYTRUDA, Merck’s anti-PD-1 therapy, to include an every-six-weeks (Q6W)...
(San Francisco Business Times) June 19, 2019 - A small San Francisco drug company offering a new protein-degrading approach to fight blood cancers and other diseases cut a potential $2.3 billion deal with giant Gilead Sciences Inc. to discover drugs that Gilead then could license.
In the multi-year deal, Foster City-based Gilead will...
There are no Lymphoma (includes NHL, HL, CNS Lymphoma) OBR Green articles.